Clinical trials
catalyst calendar across sponsors →Studies where CRDL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 3 with posted results
Held by 5 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, Point72 Asset Management, L.P.) · FINRA short interest 2.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299Recurrence of pericarditisRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Drug: CardiolRx | Recurrent Pericarditis | 110 | 2026-09-21 | in 32 d | 2026-08-13 |
| Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisNCT05180240results2026-06-17Extracellular Volume (ECV)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CardiolRx | Acute Myocarditis | 109 | 2025-01-31actual | — | 2026-06-17 |
| Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)NCT05494788results2025-10-2011-point NRS Pain ScoreOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CardiolRx | Recurrent Pericarditis | 27 | 2024-06-15actual | — | 2025-10-20 |
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949results2025-07-25Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular ComplicationsRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame. | Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo | COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor | 90 | 2022-11-30actual | — | 2026-04-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19